Article Review: Impact of Person-Centered Planning and Collaborative Documentation on Treatment Adherence (Stanhope, Ingoglia, Schmelter, & Marcus, 2013)

Purpose
Mental health providers are faced with the challenges of completing quality documentation on time, building a therapeutic alliance, and managing a client’s treatment compliance. Stanhope, Ingoglia, Schmelter, and Marcus (2013) examined the impact of person-centered planning and collaborative documentation on service engagement and medication adherence within community mental health centers (CMHC). As part of person-centered planning, collaborative documentation is being explore as a tool that works to benefit the agencies and clients by ensuring treatment services appropriately reflect the client’s values and preferences and that documentation is completed in a timely manner.

 

Background
Stanhope, Ingoglia, Schmelter, and Marcus (2013) emphasized there are challenges clinicians experience with lack of engagement in mental health services among people with a mental illness. Contributing factors to disengagement from services include mistrust in the mental health system, poor alliances with providers, a perception that providers are not listening to them, and inadequate opportunities to make decisions and collaborate in treatment. Mental health agencies are starting to place an emphasis on transparency and utilizing a collaborative approach to documentation so that it represents a true reflection of the treatment session.

 

Historically, clinicians have viewed documentation as “the enemy” because it competes with time spent with clients and many rely on “no-show” appointments to complete paperwork. Collaborative documentation can be used as a clinical tool in completing assessments, treatment plans, and progress notes together with clients during the session. This method offers clients with the opportunity to share their input and perception on services that were provided. Additionally, it allows clients and clinicians to explore important issues, clarify any misunderstandings, and focus on progress.

 

According to the researchers, person-centered planning is defined as “a highly individual comprehensive approach to assessment and services.” This treatment approach allows providers to collaborate with clients to develop customized treatment plans that identify life goals and potential barriers. Person-centered care is a structured way of organizing treatment that focus on making continuous use of strengths-based assessment strategies, recognizing appropriate supports, and empowering clients to be active participants. During this study, researchers looked to determine whether person-centered care planning combined with collaborative documentation improved service engagement and medication adherence among clients at ten geographically diverse community mental health centers (CMHCs).

 

 

Methodology
This study was a randomized controlled trial of person-centered care planning with collaborative documentation among clients receiving services at ten CMHCs. Five CMHCs were randomly assigned to the experimental condition, which provided training in person-centered planning and collaborative documentation to agency clinicians. The five CMHCs in the control condition provided treatment as usual. The study period was 11 months (May 2009 to March 2010).

 

For clients to be eligible for this study, participants were required to be aged 18 or older, have had one or more psychiatric hospitalizations or two or more psychiatric emergency room visits in the past year, have a DSM-IV axis I diagnosis, and meet at least two functional criteria of severe mental illness. Altogether, 177 clients at the CMHCs in the experimental condition and 190 clients at the CMHCs in the control condition participated.

 

The first aim of this study was to compare changes in the overall rate of clinician-reported medication adherence between clients in the experimental CMHCs and clients in the CMHCs in the control group. The provider who was best able to determine a client’s medication adherence rated adherence (yes or no) on a monthly basis for 11 months. For the second aim, client-level analyses were conducted separately for CMHCs in the experimental and control groups to examine whether the odds of medication adherence changed over time. Finally, logistic regression models, including a random effect for site, were run to calculate the effect of the intervention on the odds of an appointment no-show. The models used data received from each CMHC on the total number of appointment no-shows and the total number of appointments.

 

Conclusion
Results indicate the intervention had a positive impact on medication adherence over time. Medication adherence at CMHCs in the experimental condition increased by 2% per month over the 11-month period (B=.022, p≤.01). The control condition showed no significant change in rate of medication adherence (B=.004, p=.25), and by the end of the study, the rate of medication adherence for the control condition was lower than for the experimental condition.

 

In the client-level analyses, the odds of medication adherence over 11 months increased by 25% among clients in the experimental condition but by only 1% among clients in the control condition. An intervention effect generally was seen across client-level characteristics. Medication adherence over the 11-month study among clients with schizophrenia and bipolar disorders was significantly more improved at CMHCs in the experimental group.

 

Overall, the study found that person-centered planning and collaborative documentation were associated with greater engagement in services (a decrease in no-shows) and higher rates of medication adherence. Therefore, the study findings supported the theory that if clients have greater control over their treatment and services are genuinely oriented toward their individual goals, clients will be more engaged with services and more compliant with medication.

 

 

References
Stanhope, V., Ingoglia, C., Schmelter, B., & Marcus, S. (2013). Impact of Person-Centered Planning and Collaborative Documentation on Treatment Adherence

Psychiatric Services, 64 (1), 76–79.

 

 

Jonathan Torres, M.S.

WKPIC Doctoral Intern

Friday Factoids: Promising Long-Term Treatment for PTSD

 

Post-traumatic stress disorder (PTSD) can result from being the victim or witness to a number of traumatic events including war, an automobile accident, physical abuse, assault, homicide, and other difficult or devastating experiences. It is an equal opportunity disorder and affects men, women, and people of all cultures similarly. In the United States, PTSD has been thrown into the limelight due to the number of service men and women who are returning from active duty with this condition. The current publicity around PTSD has left many in the medical and mental health fields looking to and for variations of treatment in hopes of finding more effective, longer-lasting methods to treat this illness.

 

One of the more promising treatments, currently in Phase 2 of 3 in testing, is MDMA-Assisted Psychotherapy. MDMA (3,4-methylenedioxymethamphetamine) is a psychedelic, synthetic substance noted for its capability to help patients delve into their excruciating memories. The drug reportedly facilitates trust and compassion between the patient and therapist, all the while greatly reducing the patient’s feelings of defensiveness and terror while in session. It is believed that MDMA is able to offer this therapeutic safe haven by stimulating the release of hormones (prolactin and oxytocin) linked to bonding and trust which comforts the patient and reduces symptoms of avoidance and panic.

 

According to the research data, an astounding 83% of participants who received the treatment no longer met the guidelines for PTSD while in Phase 2 of the study.  Additionally, many of those participants reported the results lasted 3 ½ years or longer. So, why is this treatment not already approved and readily available for those who so desperately need it?

 

One potential answer to that question could be the stigma surrounding MDMA.  Most all of you have heard it referred by it street names of “Molly” or  “ecstasy.” And given so, some will not be comfortable using it as an aid during therapy even in a controlled setting providing such positive, long-term results. Secondly, the cost and time frame for each individual trial is fairly massive.  The End of Stage 2 meeting is estimated to take an additional 3 years and $2.3 million before presenting results to the FDA. Afterwards, Stage 3 is speculated to have a price tag of $15.8 million and spanning 5 years until the treatment is fully available for use with the public.

 

References
MDMA-Assisted Psychotherapy. (n.d.). Retrieved September 9, 2015, from http://www.maps.org/research/mdma

 

Treating PTSD with MDMA-Assisted Psychotherapy – Home. (n.d.). Retrieved September 8, 2015, from http://www.mdmaptsd.org/index.html

 

Crystal K. Bray, B.S.
WKPIC Doctoral Intern

Friday Factoids (Catch-Up): Special K–Are There Any Positives?

 

It was not the beginning of the zombie apocalypse that we were witnessing on the news a couple of years ago. Believe it or not, it was worse. Apparently, possible consumption of human flesh is one of the many unwanted side effects of abusing the anesthetic, Ketamine. “Special K”, as it is known on the streets, underwent a transformation into the new party drug, and it has been taking its place alongside opiates, benzodiazepines, and marijuana with teens and twenty-somethings since about 2010. Since that time, this once surgically “essential” and publically unknown drug has been drawing vast amounts of negative media, criminal and medical attention—but are there any positives associated with this drug?

 

Recently, scientists, mental health and medical professionals have discovered that medically controlled doses of Ketamine are very beneficial in treating Major Depressive Disorder and Bipolar Disorder. Yes, the same medication approved as an anesthetic in 1970, the same drug that has been abused to get high since the 2010’s, is providing evidence-based results that it does, in fact, reduce depression and regulate mood. Studies have shown that it produces significant results within a matter of minutes to hours instead of 2-3 weeks, which is the window within which standard pharmacological treatments for mood typically show benefits. Additionally, patients suffering from suicidal ideation who were treated with a “medically controlled dose” of Ketamine (medically controlled dose being key) reported their symptoms drastically reduced in 40 minutes, with gains lasting about 4 hours. Clinics around the U.S. are even currently treating patients suffering from depression and mood disorders using controlled amounts of Ketamine (yes, this is legal).

 

So Ketamine does appear to have some positives with respect to potential uses in the treatment of both unipolar and bipolar mood issues. It potentially provides treatment results, time frames and options for practitioners and patients, but the key appears to be the controlled dosing.

 

Reference
DiazGranados, N., Ibrahim, L., Brutsche, N., Ameli, R., Henter, I., Luckenbaugh, D., . . . Zarate, JR, C. (n.d.). Rapid Resolution of Suicidal Ideation after a Single Infusion of an NMDA Antagonist in Patients with Treatment-Resistant Major Depressive Disorder. J Clin Psychiatry., 71(12), 1605-1611. Retrieved September 7, 2015, from https://nebula.wsimg.com/5f3b6cc5e31881bab9f0fb5d070d35d2?AccessKeyId=98358B1A7BDF604FD210&disposition=0&alloworigin=1

 

Ketamine Facts, Effects and Treatment | Ketamine Clinics – Los Angeles, CA. (n.d.). Retrieved September 9, 2015.

 

Crystal K. Bray, BS
WKPIC Doctoral Intern

 

Farewell to the Class of 2014-2015

Summer ends, and so, too, does a year of internship at WKPIC. Good luck to Dr. Brittany Best, Dr. Graham Martin, and Dr. Faisal Roberts. Dr. Best moves on to a post-doctoral year in Hawaii (yes, we are all jealous), Dr. Martin is returning to his home state of Texas for his post-doctoral position, and Dr. Roberts is headed off to Pennsylvania for his post-doctoral year.

 

WKPIC staff knows you’ll do well wherever you go. We’re very proud of your accomplishments here–and no doubt we will hear good things about you in the future.

 

 

20150828-DSC_1116 20150828-DSC_1118